Cochlear Product Recall Costs May Exceeed A$35 Million, UBS Says

Cochlear Ltd. (COH)’s cost of voluntarily recalling its Nucleus 5 range of hearing devices because of a manufacturing glitch may exceed A$35 million, UBS said.

It’s too early to predict the product’s return to market and six months remains the “minimum estimate,” UBS Sydney- based health-care analysts Andrew Goodsall and Dan Hurren said in a report today in which they reiterated a “sell” rating on the shares.

To contact the editor responsible for this story: Jason Gale at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.